Michele Clemens
Western Pennsylvania Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Michele Clemens.
American Journal of Human Genetics | 2008
Jeff M. Milunsky; Tom A. Maher; Geping Zhao; Amy E. Roberts; Heather J. Stalker; Roberto T. Zori; Michelle N. Burch; Michele Clemens; John B. Mulliken; Rosemarie Smith; Angela E. Lin
Branchio-oculo-facial syndrome (BOFS) is a rare autosomal-dominant cleft palate-craniofacial disorder with variable expressivity. The major features include cutaneous anomalies (cervical, infra- and/or supra-auricular defects, often with dermal thymus), ocular anomalies, characteristic facial appearance (malformed pinnae, oral clefts), and, less commonly, renal and ectodermal (dental and hair) anomalies. The molecular basis for this disorder is heretofore unknown. We detected a 3.2 Mb deletion by 500K SNP microarray in an affected mother and son with BOFS at chromosome 6p24.3. Candidate genes in this region were selected for sequencing on the basis of their expression patterns and involvement in developmental pathways associated with the clinical findings of BOFS. Four additional BOFS patients were found to have de novo missense mutations in the highly conserved exons 4 and 5 (basic region of the DNA binding domain) of the TFAP2A gene in the candidate deleted region. We conclude BOFS is caused by mutations involving TFAP2A. More patients need to be studied to determine possible genetic heterogeneity and to establish whether there are genotype-phenotype correlations.
Human Molecular Genetics | 2013
Ulrike Schwarze; Tim Cundy; Shawna M. Pyott; Helena E. Christiansen; Madhuri Hegde; Ruud A. Bank; Gerard Pals; Arunkanth Ankala; Karen N. Conneely; Laurie H. Seaver; Suzanne Yandow; Ellen M. Raney; Dusica Babovic-Vuksanovic; Joan M. Stoler; Ziva Ben-Neriah; Reeval Segel; Sari Lieberman; Liesbeth Siderius; Aida Al-Aqeel; Mark C. Hannibal; Louanne Hudgins; Elizabeth McPherson; Michele Clemens; Michael D. Sussman; Robert D. Steiner; John D. Mahan; Rosemarie Smith; Kwame Anyane-Yeboa; Julia Wynn; Karen Chong
Although biallelic mutations in non-collagen genes account for <10% of individuals with osteogenesis imperfecta, the characterization of these genes has identified new pathways and potential interventions that could benefit even those with mutations in type I collagen genes. We identified mutations in FKBP10, which encodes the 65 kDa prolyl cis-trans isomerase, FKBP65, in 38 members of 21 families with OI. These include 10 families from the Samoan Islands who share a founder mutation. Of the mutations, three are missense; the remainder either introduce premature termination codons or create frameshifts both of which result in mRNA instability. In four families missense mutations result in loss of most of the protein. The clinical effects of these mutations are short stature, a high incidence of joint contractures at birth and progressive scoliosis and fractures, but there is remarkable variability in phenotype even within families. The loss of the activity of FKBP65 has several effects: type I procollagen secretion is slightly delayed, the stabilization of the intact trimer is incomplete and there is diminished hydroxylation of the telopeptide lysyl residues involved in intermolecular cross-link formation in bone. The phenotype overlaps with that seen with mutations in PLOD2 (Bruck syndrome II), which encodes LH2, the enzyme that hydroxylates the telopeptide lysyl residues. These findings define a set of genes, FKBP10, PLOD2 and SERPINH1, that act during procollagen maturation to contribute to molecular stability and post-translational modification of type I procollagen, without which bone mass and quality are abnormal and fractures and contractures result.
American Journal of Medical Genetics Part A | 2011
Jeff M. Milunsky; Tom M. Maher; Geping Zhao; Zhenyuan Wang; John B. Mulliken; David Chitayat; Michele Clemens; Heather J. Stalker; Mislen Bauer; Michele Burch; Sébastien Chénier; Michael L. Cunningham; Arlene V. Drack; Sandra Janssens; Audrey Karlea; Regan Klatt; Usha Kini; Ophir D. Klein; Augusta M. A. Lachmeijer; André Mégarbané; Nancy J. Mendelsohn; Wendy S. Meschino; Geert Mortier; Sandhya Parkash; C. Renai Ray; Angharad M. Roberts; Amy E. Roberts; Willie Reardon; Rhonda E. Schnur; Rosemarie Smith
Branchio‐oculo‐facial syndrome (BOFS; OMIM#113620) is a rare autosomal dominant craniofacial disorder with variable expression. Major features include cutaneous and ocular abnormalities, characteristic facies, renal, ectodermal, and temporal bone anomalies. Having determined that mutations involving TFAP2A result in BOFS, we studied a total of 30 families (41 affected individuals); 26/30 (87%) fulfilled our cardinal diagnostic criteria. The original family with the 3.2 Mb deletion including the TFAP2A gene remains the only BOFS family without the typical CL/P and the only family with a deletion. We have identified a hotspot region in the highly conserved exons 4 and 5 of TFAP2A that harbors missense mutations in 27/30 (90%) families. Several of these mutations are recurrent. Mosaicism was detected in one family. To date, genetic heterogeneity has not been observed. Although the cardinal criteria for BOFS have been based on the presence of each of the core defects, an affected family member or thymic remnant, we documented TFAP2A mutations in three (10%) probands in our series without a classic cervical cutaneous defect or ectopic thymus. Temporal bone anomalies were identified in 3/5 patients investigated. The occurrence of CL/P, premature graying, coloboma, heterochromia irides, and ectopic thymus, are evidence for BOFS as a neurocristopathy. Intrafamilial clinical variability can be marked. Although there does not appear to be mutation‐specific genotype–phenotype correlations at this time, more patients need to be studied. Clinical testing for TFAP2A mutations is now available and will assist geneticists in confirming the typical cases or excluding the diagnosis in atypical cases.
Genetics in Medicine | 2004
Sandra Prucka; Michele Clemens; Catherine Craven; Elizabeth McPherson
Purpose: To ascertain the frequency of chromosomal and other anomalies in fetuses with single umbilical artery.Methods: Placentas with single umbilical artery were identified from hospital pathology laboratory records. For each identified case, the next consecutive placenta with two umbilical arteries served as a control. Pathology records, maternal histories, and prenatal ultrasounds when available were reviewed for congenital anomalies, pregnancy complications, and maternal characteristics. When indicated, placental specimens, amniocytes, or neonatal bloods were karyotyped.Results: Single umbilical artery existed in 2.0% (97/4846) of pathological specimens. Fetuses with single umbilical artery had significantly more chromosomal (10.3% vs. 1.0%) and other congenital anomalies (27% vs. 8%).Conclusions: The high incidence of major chromosomal and congenital anomalies justifies detailed fetal ultrasonography, echocardiography, and amniocentesis for karyotype when single umbilical artery is discovered during routine ultrasound.
American Journal of Medical Genetics | 1998
Tracy J. Wright; Michele Clemens; Oliver Quarrell; Michael R. Altherr
Wolf-Hirschhorn syndrome (WHS), a multiple congenital malformation syndrome, and Pitt-Rogers-Danks syndrome (PRDS), a rare condition with similar anomalies, were previously thought to be clinically distinct conditions. While WHS has long been associated with deletions near the terminus of 4p, several recent studies have shown PRDS is associated with deletions in 4p16.3. In this paper we evaluate three patients, two described as PRDS and one diagnosed as WHS. We demonstrate that the molecular defects associated with the two syndromes show a considerable amount of overlap. We conclude that both of these conditions result from the absence of similar, if not identical, genetic segments and propose that the clinical differences observed between these two syndromes are likely the result of allelic variation in the remaining homologue.
American Journal of Medical Genetics | 1988
Angela E. Lin; Kenneth L. Garver; Gerard R. Diggans; Michele Clemens; Sharon L. Wenger; Mark W. Steele; Marilyn C. Jones; Jeannette Israel; John M. Opitz; James F. Reynolds
American Journal of Medical Genetics | 1995
Elizabeth McPherson; Michele Clemens; Richard J. Gibbons; Douglas R. Higgs
American Journal of Medical Genetics | 1998
Elizabeth McPherson; Michele Clemens; Lori Hoffner; Urvashi Surti
American Journal of Medical Genetics | 1993
Angela E. Lin; Elizabeth McPherson; Ngozi A. Nwokoro; Michele Clemens; H. Wolfgang Losken; John J. Mulvihill
American Journal of Medical Genetics | 1988
Angela E. Lin; Michele Clemens; Kenneth L. Garver; Sharon L. Wenger; Mark W. Steele; John M. Opitz; James F. Reynolds